AMEX:VNRX

VolitionRx Limited Releases Video of Virtual Capital Markets Day 2020

AUSTIN, Texas, Oct. 21, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, hosted a capital ma...

2020-10-21 20:00 1456

VolitionRx Limited Announces Details for Virtual Capital Markets Day 2020

AUSTIN, Texas, Oct. 20, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, will host a capital...

2020-10-20 19:00 3356

Volition Veterinary Diagnostics Development LLC Announces Product Data Regarding its Nu.Q™ Vet Cancer Screening Test in Lymphoma and Hemangiosarcoma to be Presented at the 2020 VCS Virtual Annual Conference

* Positive data show high sensitivity and specificity in the detection of Lymphoma and Hemangiosarcoma as Volition remains on target for launch of its first product expected later this year * Cancer is the most common cause of death in dogs over the age of two years old in the U.S. * Togeth...

2020-10-16 20:00 16036

VolitionRx Limited Announces Details for Virtual Capital Markets Day 2020

AUSTIN, Texas, Oct. 14, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced further d...

2020-10-14 20:00 11980

Volition Veterinary Diagnostics Development LLC to Present Product Data Regarding its Nu.Q™ Vet Cancer Screening Test at the 2020 VCS Virtual Annual Conference

AUSTIN, Oct. 12, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, will present two abstract...

2020-10-12 20:00 13757

VolitionRx Limited Announces Virtual Capital Markets Day 2020

AUSTIN, Texas, Sept. 29, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases, today announced it will host a capital market...

2020-09-29 20:00 9012

VolitionRx Limited to Present at Conferences in September 2020

AUSTIN, Texas, Sept. 1, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that its Chief Executive Officer,Cameron Reynolds, and its Executive Vice President, Investor Relations, Scott Powell, are scheduled to present at five conferences inSeptember 2020. ...

2020-09-01 20:00 14713

VolitionRx Limited Announces Second Quarter 2020 Financial Results and Business Update

AUSTIN, Texas, August 13, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the second quarter endedJune 30, 2020. Volition management will host a conference call tomorrow,August 14 at 8:30 a.m. U.S. Eastern Time...

2020-08-14 04:10 4265

VolitionRx Limited Schedules Second Quarter 2020 Earnings Conference Call and Business Update

AUSTIN, Texas, Aug. 10, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call onFriday, August 14, at 8:30 a.m. Eastern time to discuss its financial and operating results for the second quarter 2020, in addition to providing a b...

2020-08-10 19:30 7200

Volition Announces Promising Clinical Trials Results for its Novel COVID-19 Triage Test

AUSTIN, Texas, July 14, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company applying its Nu.Q™ Nucleosomics™ technology to develop simple, cost effective blood-based tests for cancer and other diseases, today announced that results from...

2020-07-14 18:00 15598

VolitionRx Releases Business Update Video and Announces Addition to the Russell 3000® and Russell Microcap® Indexes

AUSTIN, Texas, June 25, 2020 /PRNewswire/ -- VolitionRx Limited  (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost-effective blood tests to help diagnose a range of cancers and other diseases, today released ...

2020-06-25 20:45 11068

Volition Announces Cameron Reynolds, President and Chief Executive Officer Invited as Presenter at Maxim's COVID-19 Virtual Conference

AUSTIN, May 27, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that President and Chief Executive Officer,Cameron Reynolds has been invited to present at The Role of Cell Therapy and Clarity on Testing Conference organised by the Maxim Group. Event Det...

2020-05-27 20:45 9301

VolitionRx Announces Closing of $13.8 Million Public Offering of Common Stock

AUSTIN, Texas, May 22, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company that applies its NucleosomicsTM platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to hel...

2020-05-23 04:01 10561

VolitionRx Announces Pricing of Underwritten Public Offering of Common Stock

AUSTIN, Texas, May 20, 2020 /PRNewswire/ -- VolitionRx Limited  (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company that applies its NucleosomicsTM platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to hel...

2020-05-20 20:45 10185

VolitionRx Announces Proposed Underwritten Public Offering of Common Stock

AUSTIN, Texas, May 19, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a range of cancers a...

2020-05-20 04:01 7851

VolitionRx To Present First Data on Nu.Q™ Capture Performance and Nu.Q™ Assay Performance in Lung Cancer and Blood Cancer at the 2020 ASCO Annual Meeting

AUSTIN, Texas, May 13, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), an epigenetics company developing simple, easy to use and cost effective blood tests to help diagnose a range of cancers, will present three abstracts at the 2020 ASCO Annual Meeting. The first abs...

2020-05-14 06:54 7393

VolitionRx Limited Announces First Quarter 2020 Financial Results and Business Update

AUSTIN, Texas, May 7, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the first quarter endedMarch 31, 2020. Volition management will host a conference call tomorrow,May 8 at 8:30 a.m. U.S. Eastern Time to disc...

2020-05-08 04:10 9423

VolitionRx Limited Schedules First Quarter 2020 Earnings Conference Call and Business Update

AUSTIN, Texas, May 5, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call onFriday, May 8, at 8:30 a.m. Eastern time to discuss its financial and operating results for the first quarter 2020, in addition to providing a business...

2020-05-05 20:30 7868

Volition's Nu.Q™ Vet Assay Detects Two Common Canine Cancers

AUSTIN, Texas, April 29, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced results from its first proof of concept study conducted byTexas A&M University ("TAMU"). At a specificity of 90%, a single Nu.Q™ Vet assay detected almost 70% of both Canine Hemang...

2020-04-29 20:30 7787

Volition Files Patent for Nu.Q(TM) COVID-19 Triage Test and Commences Proof of Concept Studies

AUSTIN, Texas, April 23, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it is actively developing a COVID-19 triage test aiming to predict the likelihood that an individual who is COVID-19 positive will develop complications and severe disease, usi...

2020-04-23 20:30 6059
12345